Business Context and Reporting Period
Company: Geron Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: Geron is a biopharmaceutical company developing first-in-class therapies for cancer and chronic degenerative diseases. Its primary platforms focus on telomerase inhibitors (imetelstat), telomerase vaccines (GRNVAC1), and human embryonic stem cell (hESC) therapies (e.g., GRNOPC1 for spinal cord injury). The company has no approved products and relies on research and development funding, licensing, and collaboration revenues.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2010 |
Six Months Ended June 30, 2010 |
Six Months Ended June 30, 2009 |
|---|---|---|---|
| Total Revenues | $1,001 | $1,919 | $627 |
| Operating Expenses | $17,877 | $35,272 | $36,089 |
| Net Loss | $(17,031) | $(33,671) | $(36,569) |
| Net Loss Per Share (Basic/Diluted) | $(0.18) | $(0.35) | $(0.43) |
| Cash and Cash Equivalents | Balance Sheet Data (June 30, 2010): $37,315 | ||
| Total Marketable Securities | Balance Sheet Data (June 30, 2010): $117,889 | ||
| Total Liquidity (Cash + Securities) | Approx. $155.2 million | ||
| Accumulated Deficit | Balance Sheet Data (June 30, 2010): $(610,938) |
Cash Flow (Six Months Ended June 30, 2010):
- Net cash used in operating activities: $(19,171)
- Net cash provided by investing activities: $11,695
- Net cash provided by financing activities: $10,190
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased significantly to $1.9 million for the six months ended June 30, 2010, compared to $0.6 million in the prior year period. This was driven by $450,000 in revenue from collaborative agreements (specifically with GE Healthcare) and increased license fees and royalties.
- Reduced Net Loss: Net loss decreased to $33.7 million for the six months ended June 30, 2010, from $36.6 million in the comparable 2009 period. This improvement was due to increased revenues, reduced R&D expenses, and unrealized gains on derivatives.
- R&D Expenses: Research and development expenses decreased to $26.9 million (six months 2010) from $28.9 million (six months 2009). The reduction was primarily due to lower product manufacturing costs following the completion of patient enrollment in the Phase II trial of GRNVAC1 and lower preclinical study costs.
- Derivative Gains: The company recorded an unrealized gain on derivatives of $230,000 for the six months ended June 30, 2010, compared to a loss of $1.3 million in the prior year period. This shift was due to reduced fair values of derivative liabilities.
Guidance, Outlook, and Risks
Outlook and Capital Resources:
Management estimates that existing capital resources, interest income, and an equipment financing facility will be sufficient to fund operations through at least December 2011. However, the company anticipates substantial future capital requirements to advance clinical trials for imetelstat, GRNVAC1, and GRNOPC1. If additional capital is not available, the company may need to curtail operations or seek financing on unfavorable terms.
Key Developments:
- Imetelstat: Initiation of Phase II clinical trials in four malignancies is planned for 2010. The first patient was enrolled in a randomized Phase II trial for non-small cell lung cancer in July 2010.
- GRNOPC1: The FDA lifted its clinical hold on the IND application for this hESC-derived therapy for spinal cord injury. The company plans to initiate a Phase I multi-center trial.
- TA Therapeutics: In July 2010, the board of TA Therapeutics, Ltd. (a joint venture) approved a voluntary winding up. Assets and IP will be absorbed by Geron by December 31, 2010.
Risks and Contingencies:
- Regulatory Approval: The company faces significant uncertainty regarding the timing and success of regulatory approvals for its product candidates.
- Intellectual Property: Geron is involved in patent opposition proceedings in Europe regarding telomerase vaccines and hESC technologies. Outcomes are uncertain and could limit commercial rights.
- hESC Restrictions: Political and ethical opposition to human embryonic stem cell research could hinder development and market acceptance.
- Manufacturing Costs: Product candidates are likely expensive to manufacture; failure to reduce costs could impact profitability.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the ~$155 million liquidity position to fund operations through the end of 2011, considering the high burn rate of clinical trials.
- Clinical Trial Progress: Monitor enrollment and interim data for the Phase II trials of imetelstat and the upcoming Phase I trial for GRNOPC1.
- Revenue Sustainability: Assess the longevity of the GE Healthcare collaboration revenue, which is recognized ratably and expected to cease after 2011 based on current deferred revenue.
- Patent Litigation: Track the status of European patent oppositions regarding telomerase vaccines and hESC technologies, as adverse rulings could materially impact the business model.
- Financing Needs: Evaluate the likelihood and terms of future equity or debt financing required to sustain operations beyond late 2011.